Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2005-06-28
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S185100
Reexamination Certificate
active
06911430
ABSTRACT:
The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and/or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.
REFERENCES:
patent: 5888529 (1999-03-01), Bunnett et al.
patent: 5929035 (1999-07-01), Owyang
patent: 5958407 (1999-09-01), Bunnett et al.
patent: 6197333 (2001-03-01), Onyuksel et al.
patent: 6469030 (2002-10-01), Farrar et al.
patent: 6645959 (2003-11-01), Bakker-Arkema et al.
Satoh, Y. et al. J. Smooth Muscle Res. 35(3):65-75 (1999).
Bernstein, L.R. et al., “Current and Emerging Pharmacotherapy for Postoperative Ileus,” Released Apr. 30, 2002, www.medscape.com.
Abad, C. et al., “Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy.”J. Immunol.vol. 167, pp. 3182-3189 (2001).
Adamou, J.E. et al., “Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor.”Biochem. Biophys. Res. Commun.,vol. 209, pp. 385-392 (1995).
Alexandre, D. et al., “A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.”Endocrinologyvol. 140, pp. 1285-1293 (1999).
Almgren, M. et al., “Self-aggregation and phase behavior of poly(ethylene oxide)-pholy(propylene oxide)-oly(ethylene oxide) bloxk copolymers in aqueous solutions.”Colloid Polym. Sci.,vol. 273, pp. 2-15 (1995).
Andersson, A. et al., “Expression and Motor Effects of Secretin in Small and Large Intestine of the Rat.”Peptidesvol. 21, pp. 1687-1694 (2000).
Arimura, A., “Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research.”Regulatory Peptidesvol. 37, pp. 287-303 (1992).
Bauer, F.E. et al., “Changes in the Blood Gas Concentration Caused by Secretin and Cholecystokinin: Indication of a Vasomotor Effect?”J. Clin. Gastroenterol.,vol. 8, pp. 263-266 (1986).
Bayliss, W.M. et al., “The mechanism of pancreatic secretion,”J. Physiol.,vol. 28, pp. 325-353 (1902).
Bodansky, M.et al., “Conformation of Peptides of the Secretin-VIP-Glucagon Family in Solution.”Peptides,vol. 7. Supp. 1, pp. 43-48 (1986).
Bodanszky, M. et al., “A preferred conformation in the vasoactive intestinal peptide (VIP). Molecular architecture of gastrointestinal hormones.”Bioorgan. Chem.,vol. 3, pp. 133-140 (1974).
Brizzolara, A.L. et al., “Endothelium-dependent and endothelium-independent vasodilatation of the hepatic artery of the rabbit,”Br. J. Pharmacol.vol. 103, pp. 1206-1212 (1991).
Brunner, H. et al., “Secretin-Induced Bile Secretion, Bile Acid Output and Blood Supply to the Liver in the Dog,”Eur. Surg. Res.,vol. 7, pp. 205-211 (1975).
Carey, M.C. et al., “Micelle formation by the bile salts: physical-chemical and thermodynamic considerations,”Arch. Inter. Med.,vol. 130, pp. 506-527 (1972).
Carpenter, K.A. et al., “Aggregation Behaviour and Zn2+Binding Properties of Secretin,”Biochemistry,vol. 37, pp. 16969-16974 (1998).
Cauvin, A. et al., “The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK,”Peptides,vol. 11, pp. 773-777 (1990).
Chang, C.H. et al., “Modulation of secretin release by neuropeptides in secretin-producing cells,”Am. J. Physiol.vol. 275, pp. G192-202 (1998).
Chatterjee, T.K. et al., “Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels,”J. Biol. Chem.,vol. 271, pp. 32226-32232 (1996).
Chez, M.G. et al., “Secretin and autism: a two-part clinical investigation,”J. Autism. Dev. Disord.,vol. 30, pp. 87-94 (2000).
Chou, C.C. et al., “Comparison of vascular effects of gastrointestinal hormones on various organs,”Am. J. Physiol.,vol. 232, pp H103-H109 (1977).
Chow, B.K. et al., “Molecular evolution of vertebrate VIP receptors and functional characterization of a VIP receptor from goldfishCarassius auratus,” Gen. Comp. Endocrinol.,vol. 105, pp. 176-185 (1997).
Couvineau, A. et al., “Human intestinal VIP receptor: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains,”Biochem. Biophys. Res. Commun.,vol. 200, pp. 769-776 (1994).
Cullen J.J. et al., “Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide,”Dig. Dis. Sci.,vol. 39, No. 6, pp. 1179-1184 (1994).
Daniel P.B. et al., “Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis,”J. Biol. Chem.,vol. 276, pp. 12938-12944 (2001).
Dautzenberg F.M. et al., “N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants,”J. Neuroendocrinol.,vol. 11, pp. 941-949 (1999).
Davis, M.J. et al., “Microvascular pressure distribution and responses of pulmonary allografts and cheek pouch arterioles in the hamster to oxygen,”Circ. Res.,vol. 49, pp. 125-132 (1981).
De Winter, B.Y. et al., “Effect of adrenergic and intrergic blockade on experimental ileus in rats,”Br. J. Pharmacol.,vol. 120, pp. 464-468 (1997).
De Winter B.Y. et al., “Role of VIP1/PACAP receptors in postoperative ileus in rats,”Br. J. Pharmacol.vol. 124, No. 6, pp. 1181-1186 (1998).
Dickinson, T. et al., “Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs,”Neuropeptides,vol. 31, pp. 175-185 (1997).
Dow, R.C. et al., “Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat,”J. Endocrinol.,vol. 42, pp. R1-4 (1994).
Espat, N.J. et al., “Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus,” J. Surg. Res., vol. 58, No. 6, pp. 719-723 (Jun. 1995).
Filizola, M. et al., “Conformational study of vasoactive intestinal peptide by computational methods,”J. Pept.,vol. 50, pp. 55-64 (1997).
Fisher Surface Tensiomat Model 21 Catalog No. 14-814 Instruction manual.
Gandhi, S. et al., “Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo,”Peptides,vol. 23, pp. 1433-1439 (2002).
Gandhi S. et al., “Increased bioactivity of secretin in sterically stabilized micelles: Implication for therapy,”Int. Symp. Controlled Release,vol. 28, pp. 572-573 (2001).
Gandhi, S. et al., “Secretin self-assembles and interacts spontaneously with phospholipids in vitro,”Peptides,vol. 23, pp. 201-204 (2002).
Ganea, D. et al., “Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP,”Arch. Immunol. Ther. Exp.,vol. 49, pp. 101-110 (2001).
Gao, X. et al., “Vasoactive int
Desai Anand
VipoGen, LLC
Weber Jon
Winston & Strawn LLP
LandOfFree
Compositions and methods for treating ileus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating ileus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating ileus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3496894